KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC

Basit Öğe Kaydı
dc.authoridBarrios, Carlos/0000-0001-6021-667X
dc.authorwosidBarrios, Carlos/HJG-7197-2022
dc.contributor.authorCortes, J.
dc.contributor.authorCescon, D. W.
dc.contributor.authorRugo, H. S.
dc.contributor.authorIm, S-A.
dc.contributor.authorYusof, M. Md
dc.contributor.authorGallardo, C.
dc.contributor.authorLipatov, O.
dc.date.accessioned2023-01-12T19:54:23Z
dc.date.available2023-01-12T19:54:23Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.descriptionCongress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 16-21, 2021 -- ELECTR NETWORKen_US
dc.description.abstract[No Abstract Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncol,Japanese Soc Med Oncolen_US
dc.description.sponsorshipMerck Sharp Dohme Corp.en_US
dc.description.sponsorshipFunding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.en_US
dc.identifier.doi10.1016/j.annonc.2021.08.2089
dc.identifier.endpageS1290en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS1289en_US
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2021.08.2089
dc.identifier.urihttps://hdl.handle.net/11454/76401
dc.identifier.volume32en_US
dc.identifier.wosWOS:000700527703488en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleKEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBCen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu